Grab-body
Grab-LNP is an advanced targeted drug delivery system for cancer treatment, designed to overcome the limitations of conventional antibody-LNP therapies that rely on chemical binding.
With enhanced targeting specificity and productivity, it efficiently delivers therapeutic payloads directly to the target cell.
Enhancing Targeting Capability of mRNA@LNP
Our proprietary technology enables self-assembly of antibodies and lipid nanoparticles without complex chemical binding, allowing for a high density of antibodies on the lipid nanoparticle surface. This dramatically enhances the targeting capability of mRNA@LNP, making in vivo administration feasible.
Minimizing Side Effects of mRNA@LNP
Our proprietary Grab-body technology significantly reduces off-target issues in the liver, spleen, and other organs, offering a versatile and widely applicable targeted delivery platform.
Through our advanced Grab-body technology, we aim to lead the way in targeted mRNA delivery for cancer treatment, ultimately contributing to the conquest of cancer
What is Grab-body?
Overview
The Grab-body endows LNP therapeutics with exceptional targeting capability, enhancing therapeutic efficacy at the targeted site while minimizing off-target side effects.
Structure of the Grab-body
The Grab-body consists of an antibody section for targeted delivery and a Grab protein section for attachment to the LNP.
Grab-antibody LNP
The Grab-body technology enables dense antibody attachment to the LNP, greatly enhancing targeting capability. Its self-assembly method, using human-derived proteins, ensures superior stability and safety
Redefining the Future of Cancer Treatment
Grab-body
Mass Production Technology
Enables large-scale production using existing antibody manufacturing facilities
Simplifies manufacturing process through self-assembly of Grab-body and LNP
Proprietary Technology
Ensures stable binding of target-oriented domain and LNP within the human body
Offers broad and versatile application as a targeted delivery platform
High Safety
No risk of residual toxic substances due to the absence of chemical bonding process
Human-derived proteins ensure high safety and non-immunogenicity
Candidate Selection (MGB-P53)
p53
Functions as a tumor suppressor, with mutations found in nearly all cancers. The TP53 gene, responsible for producing p53, is one of the most extensively studied genes, cited in over 10,000 research papers since its discovery in 1979.
Expression of p53 and HER2
Mutations in p53 lead to overexpression of HER2
Pipeline utilizing complementary HER2 target and p53 gene delivery
Potential for Broad Applications
-
Over 3 fold higher delivery rate to target cells compared to liver cells, with a 6 fold increase in mRNA expression
-
Achieves more than 3 fold higher mRNA expression than non-targeted mRNA@LNP
-
Effectively inhibits cancer cell growth without liver toxicity
Application of Grab-antibody
Grab-mRNA@LNP can be applied across a range of cancer treatment areas, including targeted delivery for mRNA cancer therapies in solid tumors, in vivo CAR-T, cancer vaccines, gene therapy, and gene editing.
Our Goal for Grab-body
Research Achievements
0000-00-00
Title
Author
Paper
0000-00-00
Title
Author
Paper
0000-00-00
Title
Author
Paper
What is Grab-body?
LNP
LNPs became popular for vaccines due to their rapid development and safety. However, systemic administration frequently leads to liver absorption, limiting efficacy and raising the risk of side effects, posing challenges for therapeutic development.
Passive targeting LNP
Passive targeting using ionizable lipids improves tissue specificity but still faces concerns such as low expression efficiency and toxicity, without achieving cell-specific targeting
Active targeting LNP
Active targeting enhances LNP delivery but requires complex and costly manufacturing and raises toxicity concerns from residual chemical linkers
Grab-antibody LNP
While conventional LNP therapeutics struggle to balance efficient production and targeted delivery, Grab-Antibody technology enables both in one solution.